Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.

Pediatric transplantation - 1 Nov 2018

Min Sandar, Papaz Tanya, Lafreniere-Roula Myriam, Nalli Nadya, Grasemann Hartmut, Schwartz Steven M, Kamath Binita M, Ng Vicky, Parekh Rulan S, Manlhiot Cedric, Mital Seema

Abstract excerpt

BACKGROUND: Tacrolimus pharmacokinetics are influenced by age and CYP3A5 genotype with CYP3A5 expressors (CYP3A5*1/*1 or *1/*3) being fast metabolizers. However, the benefit of genotype-guided dosing in pediatric solid organ transplantation has been understudied. OBJECTIVE: To determine whether age and CYP3A5 genotype-guided starting dose of tacrolimus result in earlier attainment of therapeutic drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Organ Transplantation

Share to Pilot Projects

Share to Single-Blind Method

Share to Tacrolimus

Source

Identifiers

PMID: 30178515
DOI: 10.1111/petr.13285

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.PMID 30178515Read ↗

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.Semantic proximity Read ↗

Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.Semantic proximity Read ↗

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.Semantic proximity Read ↗

Genotype Informed Bayesian Dosing of Tacrolimus in Paediatric Solid Organ Transplant IndividualsSemantic proximity Read ↗

CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.Semantic proximity Read ↗

CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.Semantic proximity Read ↗

Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients.Semantic proximity Read ↗

An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients.Semantic proximity Read ↗

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.Semantic proximity Read ↗

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Semantic proximity Read ↗

Evaluating the evidence for genotype-informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation: A systematic literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.